Checkpoint Therapeutics
Checkpoint Therapeutics is dedicated to advancing cancer immunotherapy and targeted oncology treatments, aiming to develop accessible, effective, and potentially more affordable options for patients worldwide. The company focuses on developing and bringing cancer therapies to market faster through product purchases, in-licensing, and co-development opportunities, with a commitment to better patient outcomes and healthcare value. They have a research pipeline including several investigational medicines and have received FDA approval for UNLOXCYT™ (cosibelimab-ipdl) for metastatic and locally advanced cutaneous squamous cell carcinoma (cSCC).
Industries
Nr. of Employees
small (1-50)
Checkpoint Therapeutics
95 Sawyer Road, Suite 110, Waltham, MA 02453
Patents
Products
UNLOXCYT (cosibelimab-ipdl)
A human IgG1 anti‑PD‑L1 monoclonal antibody approved for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Cosibelimab (CK‑301) — investigational
An anti‑PD‑L1 monoclonal antibody investigated in advanced and metastatic solid tumors, including cutaneous squamous cell carcinoma.
Olafertinib (CK‑101) — investigational
An oral third‑generation irreversible kinase inhibitor targeting select EGFR activating and resistance mutations for non‑small cell lung cancer with EGFR mutations.
CK‑103 — investigational BET bromodomain inhibitor
Oral small molecule inhibitor of BET bromodomains developed for certain advanced and metastatic solid tumors.
CK‑302 — investigational anti‑GITR monoclonal antibody
A fully human agonistic antibody designed to bind GITR and trigger signaling in GITR‑expressing immune cells to potentiate antitumor immune responses.
CK‑303 — investigational anti‑CAIX monoclonal antibody
A fully human antibody designed to recognize CAIX‑expressing cells and mediate killing via ADCC and CDC, being developed for renal cell carcinoma indications.
UNLOXCYT (cosibelimab-ipdl)
A human IgG1 anti‑PD‑L1 monoclonal antibody approved for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Cosibelimab (CK‑301) — investigational
An anti‑PD‑L1 monoclonal antibody investigated in advanced and metastatic solid tumors, including cutaneous squamous cell carcinoma.
Olafertinib (CK‑101) — investigational
An oral third‑generation irreversible kinase inhibitor targeting select EGFR activating and resistance mutations for non‑small cell lung cancer with EGFR mutations.
CK‑103 — investigational BET bromodomain inhibitor
Oral small molecule inhibitor of BET bromodomains developed for certain advanced and metastatic solid tumors.
CK‑302 — investigational anti‑GITR monoclonal antibody
A fully human agonistic antibody designed to bind GITR and trigger signaling in GITR‑expressing immune cells to potentiate antitumor immune responses.
CK‑303 — investigational anti‑CAIX monoclonal antibody
A fully human antibody designed to recognize CAIX‑expressing cells and mediate killing via ADCC and CDC, being developed for renal cell carcinoma indications.
Services
In‑licensing of therapeutic assets and collaborative development arrangements with external partners.
In‑licensing of therapeutic assets and collaborative development arrangements with external partners.
Expertise Areas
- Immuno‑oncology drug development
- Monoclonal antibody therapeutics
- Small‑molecule targeted oncology drugs
- Clinical trial management (Phase I–III)
Key Technologies
- Monoclonal antibody therapeutics
- ADCC and CDC functional assays
- Phage‑display antibody discovery (referenced)
- Third‑generation irreversible EGFR kinase inhibitors
News & Updates
On May 30th, 2025, Sun Pharma completed its acquisition of Checkpoint Therapeutics, Inc.
Announcement of Sun Pharma's intention to acquire Checkpoint Therapeutics.
FDA Approval for UNLOXCYT™ (cosibelimab-ipdl)
Received FDA approval for the treatment of adults with metastatic or locally advanced cSCC.
On May 30th, 2025, Sun Pharma completed its acquisition of Checkpoint Therapeutics, Inc.
Announcement of Sun Pharma's intention to acquire Checkpoint Therapeutics.
FDA Approval for UNLOXCYT™ (cosibelimab-ipdl)
Received FDA approval for the treatment of adults with metastatic or locally advanced cSCC.